The Complete History of Psychedelics: A Timeline From Ancient Use to Modern Medicine

Humans have used psychedelic compounds for at least 9,000 years — probably much longer. The history spans every inhabited continent, every major civilization, the birth of modern pharmacology, a 50-year suppression, and a current renaissance. Here is the complete timeline.

Ancient and prehistoric era (9,000 BCE — 1500 CE)

The earliest evidence of ritual psychedelic use is cave art. At Tassili n'Ajjer in Algeria, images dated to approximately 9,000 BCE depict mushroom-shaped figures associated with religious ceremony. In Central America, mushroom stones — carved figures representing psilocybin mushrooms — date to at least 1500 BCE and appear across Maya and Aztec archaeological sites.

In the Vedic tradition of ancient India, Soma — the sacred ritual drink described in the Rigveda — is now argued by many scholars to have been a psilocybin preparation. In the ancient Mediterranean, the Eleusinian Mysteries — the most important religious ceremonies of classical Greece, lasting nearly 2,000 years — involved the ritual consumption of kykeon, a drink now widely believed to have contained ergot, an LSD-like compound.

Peyote use in what is now Mexico and the American Southwest has been documented archaeologically to at least 3,700 BCE. In the Amazon, ayahuasca has been prepared for at least 3,500 years according to current archaeological evidence.

The geographic spread is not random. Psychedelic use appears independently in South America, North America, Central America, Africa, Asia, and Europe. Multiple continents. Multiple cultures. No plausible cultural contact. The same discovery made repeatedly.

Early modern contact (1500–1900)

The Spanish conquest of Mexico in the early 16th century produced the first systematic European documentation of psychedelic use — and the first systematic suppression. Spanish clergy who documented Aztec religious practices recorded the ritual use of teonanácatl (psilocybin mushrooms) and peyote with a mixture of horror and fascination. Within decades, these practices had been driven underground, where they persisted for 400 years in indigenous communities despite active suppression.

In the 19th century, Western pharmacology began isolating active compounds. Mescaline was isolated from peyote in 1897. This marks the beginning of modern psychedelic pharmacology — the systematic extraction of consciousness-altering compounds from their plant matrices for study and, eventually, clinical use.

Scientific discovery era (1900–1950)

The early 20th century saw the first Western experimentation with mescaline, primarily by artists and intellectuals. Aldous Huxley's later work would bring these explorations to mainstream attention. More importantly, the era produced the synthesis of LSD.

Albert Hofmann, a Swiss chemist at Sandoz pharmaceutical laboratories, synthesized LSD-25 in 1938 while investigating ergot alkaloids. He set it aside. In 1943, while re-synthesizing the compound, he accidentally absorbed a trace amount — the first LSD experience in modern history. On April 19, 1943 — now known as Bicycle Day — he deliberately took a larger dose to confirm the effects. The modern psychedelic era had begun.

The golden age (1950–1970)

The two decades following Hofmann's discovery constitute the first golden age of psychedelic research. Sandoz distributed LSD as Delysid to researchers. Thousands of studies were conducted on therapeutic applications — alcoholism, anxiety, depression, trauma. Early results were promising enough to attract serious scientific attention.

In 1955, R. Gordon Wasson, an American banker and amateur mycologist, attended a Mazatec mushroom ceremony in Mexico led by healer María Sabina. His account in Life magazine introduced psilocybin mushrooms to mainstream Western awareness. Hofmann subsequently isolated psilocybin from the Psilocybe mexicana fungus in 1958.

Timothy Leary began the Harvard Psilocybin Project in 1960. Initially rigorous, the project became increasingly controversial as Leary moved from researcher to advocate. The Harvard firing in 1963, the counterculture association of psychedelics with political rebellion, and the media saturation of the mid-1960s set the political stage for what came next.

The suppression (1970–2000)

The Controlled Substances Act of 1970 placed psilocybin, LSD, mescaline, and DMT in Schedule 1 — the classification reserved for drugs with no accepted medical use and high abuse potential. In 1971, President Nixon targeted Timothy Leary specifically, calling him the most dangerous man in America.

Research stopped. Clinical trials in progress were terminated. The thousands of studies showing therapeutic promise became politically untouchable. For 25 years, essentially no human research was conducted on psychedelics.

This is the anomaly. In 9,000 years of documented human engagement with these compounds, the 1971-2000 period represents the only complete halt. What produced this suppression — and who benefited from it — is examined in the war on drugs and psychedelic suppression.

The quiet revival (2000–2015)

The revival began quietly, at a single institution. In 2006, Roland Griffiths and colleagues at Johns Hopkins published a landmark study in Psychopharmacology demonstrating that a single high-dose psilocybin session reliably produced mystical experiences in healthy volunteers — and that participants rated these experiences as among the most significant of their lives months later. The paper passed peer review. The research era had reopened.

A small number of other institutions began work. MAPS continued its MDMA research through the 2000s, building the clinical database that would eventually support FDA designation. The research base grew slowly but on rigorous methodological foundations.

The renaissance (2015–present)

From approximately 2015, the pace accelerated. FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression in 2018 and to MDMA for PTSD in 2017. Clinical trials multiplied. Coverage shifted from counterculture to clinical medicine. Michael Pollan's How to Change Your Mind (2018) reached a mainstream audience that academic papers had not.

Oregon passed Measure 109 in 2020, establishing the first legal psilocybin therapy framework in the United States. Colorado followed. As of this writing, dozens of clinical trials are active. The research that was suppressed for 30 years is returning faster than it disappeared.

The pattern across history

The full arc of this history shows something consistent: these compounds are found. Independently, repeatedly, across cultures with no contact. They are incorporated into the most important ceremonies in every culture that encounters them. They are suppressed by political power. They persist. They re-emerge.

Whatever psychedelics are, they are more persistent than the attempt to erase them.

The Technospermia reading of history

The 50-year suppression of psychedelic research from 1971 to the early 2000s is the anomaly in this history, not the norm. Humans have worked with these compounds for at least 9,000 documented years. The suppression lasted 50. The research is returning. The technology is re-emerging. Whatever these compounds are, they have proven more persistent than the attempt to erase them.

The Technospermia framework reads the full arc of this history as evidence. The compounds have been present throughout all of human history — appearing in the most sacred ceremonies of every culture that encountered them. They were systematically suppressed for 50 years. They are re-emerging through the one channel — rigorous clinical science — that the suppression could not close permanently.

Technology does not disappear when it is politically inconvenient. It waits.

For the history of the most consequential molecule in this story, read the complete history of LSD and the complete history of cannabis. For what the suppression reveals about who controls consciousness, see the war on drugs and suppression theory. For where the renaissance stands now, read what the psychedelic renaissance is.